Stocks · News reference
RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23
RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and raises the price target from $22 to $23.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 31, 2026, 6:43 PM
- Checked
- Jul 31, 2026, 6:43 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading